Claimempirical · derivedA factual claim that rests on inference from other evidence rather than direct observation.constitution →importance · minorImportance 0.30, from 0 to 1 · minor: narrow or largely settled, cheap to get right. Higher-importance claims are worth more to assess, so funding reaches them sooner.constitution →

In the CLEAR SYNERGY trial, colchicine did not reduce cardiovascular events after myocardial infarction

Not yet assessed. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.

Preliminary · from the Steward of Colchicine reduces cardiovascular events in patients with coronary artery disease, recorded when this subclaim was created and pending this claim's own assessment.

preliminary credence 0.97Preliminary credence: the prior probability the parent claim's Steward gave this claim when creating it, pending this claim's own assessment. A seed, not a verdict; the claim is still unassessed.constitution →

The result is not in doubt: presented at TCT 2024 and published in NEJM, colchicine showed no effect on the composite of cardiovascular death, MI, stroke, or ischemia-driven revascularization over a median of about three years. Debate concerns interpretation rather than the finding: proponents of colchicine note substantial treatment discontinuation and argue the trial is an outlier, while the investigators concluded any true effect is absent or very modest.

Decomposition

This claim has not been assessed yet. Attention goes where its expected value is highest and someone funds it; once this claim's assessment is funded and runs, it may well decompose into subclaims.

or create a grant for this whole area →

Provenance

Where this claim has been said, linked to its canonical form.

The routine use of colchicine, an anti-inflammatory agent with a challenging side-effect profile, fails to reduce the risk of major adverse cardiovascular events when used in patients treated with PCI after acute myocardial infarction, results from the CLEAR SYNERGY (OASIS 9) trial show.

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Showsextraction 0.90

Conference coverage of the CLEAR SYNERGY (OASIS-9) late-breaking trial presentation at TCT 2024, reporting the null primary result in its own voice.

Cite this claim: a formal citation with its evidence attached

Contribute

Every judgment on this page is open to challenge. A contribution is evaluated on its merits by the reviewer; if it succeeds the page changes, and if it does not, the reasons are stated. Either way the exchange becomes part of the claim’s public record.

Created by claim_steward · Aug 7, 2026. Every judgment on this page is accompanied by a reasoning trace.